Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1948 1
1957 1
1965 1
1971 3
1972 3
1981 1
1990 2
1998 1
1999 2
2001 2
2005 1
2006 1
2008 2
2009 3
2014 1
2016 1
2017 1
2018 5
2019 2
2020 3
2021 7
2022 6
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Barbui T, et al. Among authors: scaffidi l. Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18. Lancet Haematol. 2021. PMID: 33476571 Clinical Trial.
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.
Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, Masciulli A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Barbui T, et al. Among authors: scaffidi l. NEJM Evid. 2023 Jun;2(6):EVIDoa2200335. doi: 10.1056/EVIDoa2200335. Epub 2023 May 15. NEJM Evid. 2023. PMID: 38320126 Clinical Trial.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, Tieghi A, Heidel FH, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Biondo M, Venturi M, Scaffidi L, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Bartoletti D, Paglia S, Vianelli N, Cavo M, Bonifacio M, Palumbo GA. Palandri F, et al. Among authors: scaffidi l. Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18. Cancer. 2023. PMID: 36932983 Free article.
Cytopenia was defined as: leukocyte count <4 10(9) /L and/or hemoglobin <11/<10 g/dL (males/females) and/or platelets <100 10(9) /L. RESULTS: Overall, 407 (45.9%) patients had a cytopenic MF, including 249 (52.4%) with PMF. ...
Cytopenia was defined as: leukocyte count <4 10(9) /L and/or hemoglobin <11/<10 g/dL (males/females) and/or platelets <10 …
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Barbui T, Carobbio A, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, Fenili F, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Calabresi L, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Ramundo F, Lunghi F, Scaffidi L, Bucelli C, Cattaneo D, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A, Vannucchi AM. Barbui T, et al. Among authors: scaffidi l. Ann Hematol. 2024 Feb;103(2):437-442. doi: 10.1007/s00277-023-05577-9. Epub 2023 Dec 7. Ann Hematol. 2024. PMID: 38060001 Clinical Trial.
In patients with low-risk polycythemia vera, exposure to low-dose Ropeginterferon alfa-2b (Ropeg) 100 g every 2 weeks for 2 years was more effective than the standard treatment of therapeutic phlebotomy in maintaining target hematocrit (HCT) (< 45%) with a reduction in …
In patients with low-risk polycythemia vera, exposure to low-dose Ropeginterferon alfa-2b (Ropeg) 100 g every 2 weeks for 2 years was …
Global trends in training and credentialing guidelines for gastrointestinal endoscopy: a systematic review.
Sabrie N, Khan R, Seleq S, Homsi H, Gimpaya N, Bansal R, Scaffidi MA, Lightfoot D, Grover SC. Sabrie N, et al. Among authors: scaffidi ma. Endosc Int Open. 2023 Feb 23;11(2):E193-E201. doi: 10.1055/a-1981-3047. eCollection 2023 Feb. Endosc Int Open. 2023. PMID: 36845269 Free PMC article. Review.
Data were collected on procedures included in each document (e. g. colonoscopy, ERCP) and types of credentialing statements (procedural volume, key performance indicators (KPIs), and competency assessments). ...
Data were collected on procedures included in each document (e. g. colonoscopy, ERCP) and types of credentialing statements (procedur …
Patient and Public Involvement in Inflammatory Bowel Disease Research-A Scoping Review.
Elsolh K, Li A, Hu M, Seleq S, Neary E, Gimpaya N, Scaffidi MA, Kishibe T, Khan R, Grover SC. Elsolh K, et al. Among authors: scaffidi ma. J Can Assoc Gastroenterol. 2023 Dec 14;7(2):137-148. doi: 10.1093/jcag/gwad054. eCollection 2024 Apr. J Can Assoc Gastroenterol. 2023. PMID: 38596798 Free PMC article. Review.
Covid19/IT the digital side of Covid19: A picture from Italy with clustering and taxonomy.
Bonnici V, Cicceri G, Distefano S, Galletta L, Polignano M, Scaffidi C. Bonnici V, et al. Among authors: scaffidi c. PLoS One. 2022 Jun 9;17(6):e0269687. doi: 10.1371/journal.pone.0269687. eCollection 2022. PLoS One. 2022. PMID: 35679235 Free PMC article.
A significant contribution to their success comes from the computer science and information technology communities, both in support to other disciplines and as the primary driver of solutions for, e.g., diagnostics, social distancing, and contact tracing. In this work, we …
A significant contribution to their success comes from the computer science and information technology communities, both in support to other …
Cyanoacrylate glue in the management of gastric varices.
Consolo P, Luigiano C, Giacobbe G, Scaffidi MG, Pellicano R, Familiari L. Consolo P, et al. Among authors: scaffidi mg. Minerva Med. 2009 Feb;100(1):115-21. Epub 2008 Dec 15. Minerva Med. 2009. PMID: 19078888 Review.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F. Polverelli N, et al. Among authors: scaffidi l. Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192. Epub 2020 Nov 21. Br J Haematol. 2021. PMID: 33222197 Free article.
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M. Palandri F, et al. Among authors: scaffidi l. Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1. Blood Cancer J. 2021. PMID: 33414394 Free PMC article. No abstract available.
57 results